

# Wenying Yang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5715539/publications.pdf>

Version: 2024-02-01

94  
papers

6,022  
citations

196777

29  
h-index

81351

76  
g-index

102  
all docs

102  
docs citations

102  
times ranked

8569  
citing authors

#	ARTICLE	IF	CITATIONS
1	Postprandial Glucose Excursions in Asian Versus Non-Asian Patients with Type 2 Diabetes: A Post Hoc Analysis of Baseline Data from Phase 3 Randomised Controlled Trials of IDegAsp. <i>Diabetes Therapy</i> , 2022, 13, 311.	1.2	1
2	Efficacy and safety benefits of <sc>iGlarLixi</sc> versus insulin glargine 100â€™%U/<sc>mL</sc> or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The <sc>LixiLanâ€™Oâ€™AP</sc> randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1522-1533.	2.2	9
3	Unmet Needs of Glycaemic Control and Risk Factors of Residual Hyperglycaemia inÂa Chinese Population with TypeÂ2 Diabetes Initiating Basal Insulin: A Post Hoc Analysis of the FPG GOAL Study. <i>Advances in Therapy</i> , 2022, , .	1.3	0
4	Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. <i>Nature Medicine</i> , 2022, 28, 974-981.	15.2	31
5	Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. <i>Nature Medicine</i> , 2022, 28, 965-973.	15.2	33
6	Maternal and paternal histories differentially influence risks for diabetes, insulin secretion and insulin resistance in a Chinese population. <i>Journal of Diabetes Investigation</i> , 2021, 12, 434-445.	1.1	7
7	Efficacy and safety of linagliptin as addâ€™on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, doubleâ€™blind, placeboâ€™controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 642-647.	2.2	4
8	Efficacy and safety of polyethylene glycol loxenate monotherapy in type 2 diabetes patients: A multicentre, randomized, doubleâ€™blind, placeboâ€™controlled phase <sc>3a</sc> clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 116-124.	2.2	17
9	Family History of Diabetes and the Effectiveness of Lifestyle Intervention on Insulin Secretion and Insulin Resistance in Chinese Individuals with Metabolic Syndrome. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-9.	1.0	2
10	Efficacy and Safety of Glucagon-Like PeptideÂ1 Receptor Agonists for the Treatment of TypeÂ2 Diabetes Mellitus: A Network Meta-analysis. <i>Advances in Therapy</i> , 2021, 38, 1470-1482.	1.3	10
11	Gender-differential effects on blood glucose levels between acarbose and metformin in Chinese patients with newly diagnosed type 2 diabetes: a sub-analysis of the MARCH trial. <i>Endocrine Journal</i> , 2021, 68, 69-79.	0.7	10
12	Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 Diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 4451-4458.	1.1	3
13	Influence of Fasting Plasma Glucose Targets on Glycemic Variability in Chinese Participants With Type 2 Diabetes: A Post Hoc Analysis of the FPG GOAL Trial (BEYOND III). <i>Advances in Therapy</i> , 2021, , 1.	1.3	1
14	Earlyâ€™onset type 2 diabetes is associated with genetic variants ofÂÎ²â€™cell function in the Chinese Han population. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3214.	1.7	14
15	Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINAÂ® trial. <i>Diabetology International</i> , 2020, 11, 129-141.	0.7	17
16	Influence of Fasting Glucose Levels on Achieving Glycemic Target in Individuals with TypeÂ2 Diabetes: a Post Hoc Analysis. <i>Advances in Therapy</i> , 2020, 37, 3816-3826.	1.3	1
17	Prevalences and associated factors of electrocardiographic abnormalities in Chinese adults: a cross-sectional study. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 414.	0.7	14
18	Glucose outcomes of a learning-type artificial pancreas with an unannounced meal in type 1 diabetes. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 191, 105416.	2.6	10

#	ARTICLE	IF	CITATIONS
19	Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment ( ORBIT ). Journal of Diabetes, 2020, 12, 668-676.	0.8	6
20	Stronger associations of waist circumference and waist-to-height ratio with diabetes than BMI in Chinese adults. Diabetes Research and Clinical Practice, 2019, 147, 9-18.	1.1	34
21	Genotypic and phenotypic spectra of hemojuvelin mutations in primary hemochromatosis patients: a systematic review. Orphanet Journal of Rare Diseases, 2019, 14, 171.	1.2	20
22	Sexual Dimorphism of a Genetic Risk Score for Obesity and Related Traits among Chinese Patients with Type 2 Diabetes. Obesity Facts, 2019, 12, 328-343.	1.6	7
23	Determining the optimal fasting glucose target for patients with type 2 diabetes: Results of the multicentre, open-label, randomized-controlled FPG GOAL trial. Diabetes, Obesity and Metabolism, 2019, 21, 1973-1977.	2.2	12
24	Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs. Diabetes Research and Clinical Practice, 2019, 150, 158-166.	1.1	4
25	Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial. Diabetes, Obesity and Metabolism, 2019, 21, 1652-1660.	2.2	16
26	Comparison of therapeutic effects of acarbose and metformin under different $\beta$ -cell function status in Chinese patients with type 2 diabetes. Endocrine Journal, 2019, 66, 443-450.	0.7	7
27	Identification of autoimmune type 1 diabetes and multiple organ-specific autoantibodies in adult-onset non-insulin-requiring diabetes in China: A population-based multicentre nationwide survey. Diabetes, Obesity and Metabolism, 2019, 21, 893-902.	2.2	24
28	Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Hepatology, 2019, 69, 2414-2426.	3.6	162
29	15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes. Drugs in R and D, 2018, 18, 27-39.	1.1	10
30	Relative Contribution of Fasting and Postprandial Blood Glucose in Overall Glycemic Control: Post Hoc Analysis of a Phase IV Randomized Trial. Diabetes Therapy, 2018, 9, 987-999.	1.2	5
31	Factors That Influence Pancreatic Beta Cell Function and Insulin Resistance in Newly Diagnosed Type 2 Diabetes Patients: A Sub-Analysis of the MARCH Trial. Diabetes Therapy, 2018, 9, 743-752.	1.2	8
32	Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. American Heart Journal, 2018, 199, 170-175.	1.2	5
33	Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial. Journal of Diabetes, 2018, 10, 589-599.	0.8	41
34	Distribution and related factors of cardiometabolic disease stage based on body mass index level in Chinese adults—The National Diabetes and Metabolic Disorders Survey. Diabetes/Metabolism Research and Reviews, 2018, 34, e2963.	1.7	4
35	Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The Goal randomized trial. Diabetes, Obesity and Metabolism, 2018, 20, 335-343.	2.2	24
36	Metformin or Acarbose Treatment Significantly Reduced Albuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Low-Grade Albuminuria. Medical Science Monitor, 2018, 24, 8941-8949.	0.5	8

#	ARTICLE	IF	CITATIONS
37	Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients. <i>Journal of Diabetes</i> , 2017, 9, 158-167.	0.8	24
38	“Learning” Can Improve the Blood Glucose Control Performance for Type 1 Diabetes Mellitus. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 41-48.	2.4	51
39	Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in China. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 822-830.	2.2	45
40	Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial. <i>Science China Life Sciences</i> , 2017, 60, 225-238.	2.3	20
41	Comparative effectiveness and safety of different basal insulins in a real-world setting. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1116-1126.	2.2	11
42	The characteristics of newly diagnosed adult early-onset diabetes: a population-based cross-sectional study. <i>Scientific Reports</i> , 2017, 7, 46534.	1.6	34
43	Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study. <i>Diabetes Therapy</i> , 2017, 8, 887-898.	1.2	2
44	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 877-886.	5.5	245
45	Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study. <i>Diabetes/Metabolism Research and Reviews</i> , 2017, 33, e2863.	1.7	7
46	Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis. <i>Journal of Diabetes</i> , 2017, 9, 787-799.	0.8	16
47	Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial. <i>Journal of Diabetes</i> , 2016, 8, 796-808.	0.8	45
48	A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus. <i>Drugs in R and D</i> , 2016, 16, 239-249.	1.1	32
49	Subject-driven titration of biphasic insulin aspart30 twice daily is non-inferior to investigator-driven titration in Chinese patients with type 2 diabetes inadequately controlled with premixed human insulin: A randomized, open-label, parallel-group, multicenter trial. <i>Journal of Diabetes Investigation</i> , 2016, 7, 85-93.	1.1	5
50	Changes in Mortality in People With IGT Before and After the Onset of Diabetes During the 23-Year Follow-up of the Da Qing Diabetes Prevention Study. <i>Diabetes Care</i> , 2016, 39, 1550-1555.	4.3	30
51	Assessment of three fasting plasma glucose targets for insulin glargine-based therapy in people with type 2 diabetes mellitus in China: study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 470.	0.7	4
52	Relationship between glycated albumin and glycated hemoglobin according to glucose tolerance status: A multicenter study. <i>Diabetes Research and Clinical Practice</i> , 2016, 115, 17-23.	1.1	23
53	Factors that influence the efficacy of acarbose and metformin as initial therapy in Chinese patients with newly diagnosed type 2 diabetes: a subanalysis of the MARCH trial. <i>Current Medical Research and Opinion</i> , 2016, 32, 713-719.	0.9	1
54	Cigarette Smoking Is Associated with a Lower Prevalence of Newly Diagnosed Diabetes Screened by OGTT than Non-Smoking in Chinese Men with Normal Weight. <i>PLoS ONE</i> , 2016, 11, e0149234.	1.1	15

#	ARTICLE	IF	CITATIONS
55	Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 537-544.	1.7	16
56	Efficacy and Safety of Tangshen Formula on Patients with Type 2 Diabetic Kidney Disease: A Multicenter Double-Blinded Randomized Placebo-Controlled Trial. <i>PLoS ONE</i> , 2015, 10, e0126027.	1.1	61
57	Sex-Specific Prevalence of Diabetes and Cardiovascular Risk Factors in the Middle-Aged Population of China: A Subgroup Analysis of the 2007-2008 China National Diabetes and Metabolic Disorders Study. <i>PLoS ONE</i> , 2015, 10, e0139039.	1.1	17
58	Cardiovascular and All-Cause Mortality Over a 23-Year Period Among Chinese With Newly Diagnosed Diabetes in the Da Qing IGT and Diabetes Study. <i>Diabetes Care</i> , 2015, 38, 1365-1371.	4.3	63
59	Branched-chain amino acids and the association with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2015, 6, 369-370.	1.1	36
60	Insulin resistance is not independently associated with chronic kidney disease in Chinese population: A population-based cross-sectional study. <i>Clinica Chimica Acta</i> , 2015, 448, 232-237.	0.5	7
61	Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China—Study Design and Baseline Characteristics. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 735-744.	2.4	33
62	Depression in Chinese patients with type 2 diabetes: associations with hyperglycemia, hypoglycemia, and poor treatment adherence. <i>Journal of Diabetes</i> , 2015, 7, 800-808.	0.8	81
63	Vildagliptin added to sulfonylurea improves glycemc control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2015, 6, 369-370.	0.8	18
64	Association between Family History Risk Categories and Prevalence of Diabetes in Chinese Population. <i>PLoS ONE</i> , 2015, 10, e0117044.	1.1	31
65	Genetic Variants Associated with Lipid Profiles in Chinese Patients with Type 2 Diabetes. <i>PLoS ONE</i> , 2015, 10, e0135145.	1.1	12
66	The Association of Type 2 Diabetes Loci Identified in Genome-Wide Association Studies with Metabolic Syndrome and Its Components in a Chinese Population with Type 2 Diabetes. <i>PLoS ONE</i> , 2015, 10, e0143607.	1.1	41
67	Cross-Sectional and Longitudinal Replication Analyses of Genome-Wide Association Loci of Type 2 Diabetes in Han Chinese. <i>PLoS ONE</i> , 2014, 9, e91790.	1.1	17
68	Obesity-Related Genomic Loci Are Associated with Type 2 Diabetes in a Han Chinese Population. <i>PLoS ONE</i> , 2014, 9, e104486.	1.1	25
69	Early therapy for type 2 diabetes in China. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 992-1002.	5.5	54
70	Association of serine racemase gene variants with type 2 diabetes in the Chinese Han population. <i>Journal of Diabetes Investigation</i> , 2014, 5, 286-289.	1.1	8
71	Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 935-943.	5.5	210
72	Albuminuria: Prevalence, associated risk factors and relationship with cardiovascular disease. <i>Journal of Diabetes Investigation</i> , 2014, 5, 464-471.	1.1	28

#	ARTICLE	IF	CITATIONS
73	Improvements in quality of life associated with biphasic insulin aspart 30 in type 2 diabetes patients in China: results from the A1chieve® observational study. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 137.	1.0	10
74	Acarbose vs metformin for new-onset type 2 diabetes – Author's reply. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 105.	5.5	0
75	BMI and waist circumference are associated with impaired glucose metabolism and type 2 diabetes in normal weight Chinese adults. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 470-476.	1.2	43
76	Metabolic syndrome and chronic kidney disease in general Chinese adults: Results from the 2007–08 China National Diabetes and Metabolic Disorders Study. <i>Clinica Chimica Acta</i> , 2014, 430, 115-120.	0.5	31
77	Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 46-55.	5.5	134
78	Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. <i>American Heart Journal</i> , 2014, 168, 23-29.e2.	1.2	50
79	Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 474-480.	5.5	535
80	MARCH2: Comparative Assessment of Therapeutic Effects of Acarbose and Metformin in Newly Diagnosed Type 2 Diabetes Patients. <i>PLoS ONE</i> , 2014, 9, e105698.	1.1	18
81	Biphasic insulin aspart 30 improved glycemic control in Chinese patients with type 2 diabetes poorly controlled on oral glucose-lowering drugs: a subgroup analysis of the A1chieve study. <i>Chinese Medical Journal</i> , 2014, 127, 208-12.	0.9	2
82	Measuring depressive symptoms using the Patient Health Questionnaire-9 in Hong Kong Chinese subjects with type 2 diabetes. <i>Journal of Affective Disorders</i> , 2013, 151, 660-666.	2.0	54
83	Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naïve subjects with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2013, 29, 1599-1608.	0.9	15
84	GW24-e3987 – Economic Burden of Cardiovascular Disease in China: A systematic review. <i>Heart</i> , 2013, 99, A289-A289.	1.2	0
85	Relationship between HbA1c and Continuous Glucose Monitoring in Chinese Population: A Multicenter Study. <i>PLoS ONE</i> , 2013, 8, e83827.	1.1	29
86	A prospective study to optimize insulin treatment by switching to insulin glargine in type 2 diabetic patients previously uncontrolled on premixed insulin: the optimization study. <i>Current Medical Research and Opinion</i> , 2012, 28, 533-541.	0.9	12
87	The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. <i>Journal of Diabetes</i> , 2012, 4, 227-237.	0.8	56
88	Serum Lipids and Lipoproteins in Chinese Men and Women. <i>Circulation</i> , 2012, 125, 2212-2221.	1.6	154
89	Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial. <i>Diabetes Research and Clinical Practice</i> , 2011, 94, 217-224.	1.1	87
90	Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study. <i>Current Medical Research and Opinion</i> , 2010, 26, 101-107.	0.9	9

#	ARTICLE	IF	CITATIONS
91	Prevalence of Diabetes among Men and Women in China. <i>New England Journal of Medicine</i> , 2010, 362, 1090-1101.	13.9	2,685
92	Observational studies: going beyond the boundaries of randomized controlled trials. <i>Diabetes Research and Clinical Practice</i> , 2010, 88, S3-S9.	1.1	117
93	Biphasic Insulin Aspart 30 Three Times Daily Is More Effective Than a Twice-Daily Regimen, Without Increasing Hypoglycemia, in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Drugs. <i>Diabetes Care</i> , 2008, 31, 852-856.	4.3	32
94	Comparative efficacy and safety of two insulin aspart formulations (Rapilin and NovoRapid) when combined with metformin, for patients with diabetes mellitus: a multicenter, randomized, open-label, controlled clinical trial. <i>Current Medical Research and Opinion</i> , 0, , 1-34.	0.9	0